New York-based Apis Capital Advisors acquired 776,000 shares of Celcuity Inc. (NASDAQ:CELC) in the third quarter, totaling $38.3 million. This represents 8.5% of the fund’s assets under management. CELC shares have surged by 669% in the past year, outperforming the S&P 500.

Celcuity Inc. is a clinical-stage biotech firm specializing in precision oncology solutions. Their lead candidate Gedatolisib and CELsignia platform aim to improve personalized cancer treatment outcomes. With a market cap of $4.6 billion, Celcuity focuses on targeting abnormal cellular signaling in cancer.

Apis Capital Advisors’ new position in Celcuity signals confidence in the company’s potential. The stock has soared over 650% in a year, making it a top holding for the fund. Celcuity’s advancements in oncology and diagnostics aim to revolutionize cancer treatment. They recently submitted an FDA application for gedatolisib.

The fund’s move into Celcuity’s stock reflects a growing belief in the company’s future success. Celcuity’s innovative approach to cancer treatment, focusing on PAM-pathway signaling, has garnered investor interest. With positive clinical results and platform progress, Celcuity aims to revolutionize personalized oncology.

Investors looking for high-growth opportunities in the biotech sector may find Celcuity’s innovative approach appealing. With a focus on precision oncology and personalized medicine, the company’s advancements in cancer treatment could lead to significant milestones in the future.

Read more at Yahoo Finance: This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results